NOVANTRONE Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Novantrone, and what generic alternatives are available?

Novantrone is a drug marketed by Emd Serono and is included in one NDA.

The generic ingredient in NOVANTRONE is mitoxantrone hydrochloride. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the mitoxantrone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Novantrone

A generic version of NOVANTRONE was approved as mitoxantrone hydrochloride by FRESENIUS KABI USA on April 11^th, 2006.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for NOVANTRONE?
What are the global sales for NOVANTRONE?
What is Average Wholesale Price for NOVANTRONE?

Summary for NOVANTRONE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	111
Clinical Trials:	71
DailyMed Link:	NOVANTRONE at DailyMed

Drug patent expirations by year for NOVANTRONE

Recent Clinical Trials for NOVANTRONE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gerhard C Hildebrandt	Phase 1
Astellas Pharma Inc	Phase 1
Eli Lilly and Company	Phase 1

See all NOVANTRONE clinical trials

US Patents and Regulatory Information for NOVANTRONE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Emd Serono	NOVANTRONE	mitoxantrone hydrochloride	INJECTABLE;INJECTION	019297-001	Dec 23, 1987		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Emd Serono	NOVANTRONE	mitoxantrone hydrochloride	INJECTABLE;INJECTION	019297-002	Dec 23, 1987		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Emd Serono	NOVANTRONE	mitoxantrone hydrochloride	INJECTABLE;INJECTION	019297-003	Dec 23, 1987		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for NOVANTRONE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Emd Serono	NOVANTRONE	mitoxantrone hydrochloride	INJECTABLE;INJECTION	019297-001	Dec 23, 1987	⤷ Sign Up	⤷ Sign Up
Emd Serono	NOVANTRONE	mitoxantrone hydrochloride	INJECTABLE;INJECTION	019297-001	Dec 23, 1987	⤷ Sign Up	⤷ Sign Up
Emd Serono	NOVANTRONE	mitoxantrone hydrochloride	INJECTABLE;INJECTION	019297-001	Dec 23, 1987	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for NOVANTRONE

See the table below for patents covering NOVANTRONE around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Switzerland	644840	BASISCH SUBSTITUIERTE ANTHRACHINONE UND DIHYDROANTHRACHINONE, IHRE HERSTELLUNG UND PHARMAZEUTISCHE ZUBEREITUNGEN.	⤷ Sign Up
Norway	150482		⤷ Sign Up
Japan	S5463064	TUMOR CONTROL AGENT	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for NOVANTRONE

Recent Clinical Trials for NOVANTRONE

Make Better Decisions: Try a trial or see plans & pricing